Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?

Vicente Valero; Gabriel N. Hortobágyi

doi:10.1200/jco.2003.11.071

March 13, 2003Journal of Clinical Oncology

Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.11.071 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12637456 Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer? Vicente ValeroxVicente ValeroSearch for articles by this author , Gabriel N. HortobagyixGabriel N. HortobagyiSearch for articles by this author Show More The University of Texas M.D. Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.2003.11.071 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Valero et al. (2003) studied this question.

synapsesocial.com/papers/6a943e8509f426568000feb4 https://doi.org/10.1200/jco.2003.11.071

View at Publisher

Ask AI

Bookmark

Share

Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?

Ask about this paper

Abstract

Discussion

Cite This Study

Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading